3 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
Follow Bone Marrow Neoplasms: new trials by email Literature Review of Bone Marrow Neoplasms trials Research Report on Bone Marrow Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera Open-label rusfertide - Polycythemia Vera | Phase 3 | Active not recruiting | Protagonist Therapeutics, Inc. | 46 | 2024-01-22 | 2025-08-06 |
| A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101) - Polycythemia Vera | Phase 3 | Active not recruiting | PharmaEssentia | 111 | 2022-10-26 | 2025-08-13 |
| A Study of Rusfertide in Adults With Polycythemia Vera (PV) Rusfertide, Placebo - Polycythemia Vera | Phase 3 | Active not recruiting | Protagonist Therapeutics, Inc. | 293 | 2022-04-11 | 2026-10-19 |
Polycythemia Vera (3) · Polycythemia (1) · Thrombocythemia, Essential (1)
Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hematologic Neoplasms (3) · Hemic and Lymphatic Diseases (3) · Myeloproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Site (3) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Hemorrhagic Disorders (1) · Thrombocytosis (1)
Protagonist Therapeutics, Inc. (2) · PharmaEssentia (1)
United States (3) · Canada (2) · Australia (1) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Israel (1) · Italy (1) · Mexico (1) · Netherlands (1)
2023 (1)